8-K: Bio-Path Holdings Secures $161,000 in Financing via Promissory Note with 1800 Diagonal Lending LLC

Bio-Path Holdings enters into a securities purchase agreement for a $161,000 promissory note with 1800 Diagonal Lending LLC, featuring a 12% interest charge and potential conversion to common stock upon default.

Summary

• Bio-Path Holdings, Inc. has entered into a securities purchase agreement with 1800 Diagonal Lending LLC for a promissory note with a principal amount of $161,000.
• The purchase price for the note is $140,000, reflecting an original issue discount of $21,000.
• The note carries a one-time interest charge of 12% applied on the issuance date, March 6, 2025.
• The note is to be repaid in five payments starting August 30, 2025, with an initial payment of $90,160 followed by four payments of $22,540 each.
• Upon an Event of Default, the note becomes immediately due and payable, with the lender entitled to 150% of the outstanding principal, accrued interest, default interest (at 22% per annum), and any amounts owed under the conversion right.
• The lender has the option to convert the outstanding principal and interest into common stock at a conversion price equal to 65% of the lowest closing bid price for the ten trading days prior to the conversion date, but cannot own more than 4.99% of the company's outstanding common stock after conversion.
• The issuance of the note and any shares issued upon conversion will not be registered under the Securities Act of 1933 and will rely on exemptions from registration.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the financing provides needed capital, the terms are somewhat onerous, suggesting potential financial strain. The conversion option introduces a dilution risk for existing shareholders.

Positives

• Bio-Path Holdings secures immediate financing of $140,000.
• The company has the right to prepay the note in full at any time with no prepayment penalty.
• The agreement contains standard and customary representations and warranties, agreements and obligations, and events of default.

Negatives

• The note carries a high default interest rate of 22% per annum.
• The lender can demand 150% of the outstanding amount upon an event of default.
• The lender has the option to convert the outstanding principal and interest into common stock at a conversion price equal to 65% of the lowest closing bid price for the ten trading days prior to the conversion date, which could dilute existing shareholders.

Risks

• Failure to make timely payments on the note constitutes an Event of Default.
• Breach of any material covenant or representation could trigger an Event of Default.
• The lender has the right to convert the debt to equity which could dilute existing shareholders.
• The company's obligations under the note could be accelerated upon certain events such as bankruptcy, delisting of common stock, or failure to comply with the Exchange Act.

Future Outlook

The company intends to use the proceeds from the note for general working capital purposes.

Industry Context

Financing agreements like this are common in the biotech industry, especially for companies in the development stage. These agreements provide necessary capital but can also introduce risks related to debt repayment and potential dilution.

Comparison to Industry Standards

• The interest rate and default terms appear relatively high compared to traditional bank loans, suggesting Bio-Path Holdings may have limited access to conventional financing.
• The conversion feature is a common structure in biotech financing, allowing lenders to participate in potential upside while providing capital to the company.
• Similar deals in the biotech space often involve warrants or other equity kickers to compensate lenders for the risk involved.

Stakeholder Impact

• Shareholders face potential dilution if the lender converts the note into common stock.
• Employees benefit from the company's ability to fund operations.
• The company's creditors are impacted by the new debt obligation.

Next Steps

• Bio-Path Holdings will make five payments to 1800 Diagonal Lending LLC, starting August 30, 2025.
• The company will need to manage its cash flow to meet its debt obligations.
• The company must comply with the covenants in the purchase agreement and note to avoid an event of default.

Key Dates